NovaBay Pharmaceuticals, Inc. (NYSEAMERICAN:NBY) has received an average recommendation of “Hold” from the eight research firms that are presently covering the company, MarketBeat reports. Two analysts have rated the stock with a sell rating, one has assigned a hold rating and five have given a buy rating to the company. The average 12 month price target among brokers that have updated their coverage on the stock in the last year is $6.60.

A number of research firms have recently issued reports on NBY. Maxim Group reissued a “hold” rating on shares of NovaBay Pharmaceuticals in a research report on Friday, August 11th. HC Wainwright set a $6.00 price target on NovaBay Pharmaceuticals and gave the stock a “buy” rating in a research report on Friday, August 11th. Zacks Investment Research raised NovaBay Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Wednesday, August 16th. Laidlaw dropped their price target on NovaBay Pharmaceuticals from $10.00 to $8.00 and set a “buy” rating on the stock in a research report on Wednesday, November 15th. Finally, dropped their price target on NovaBay Pharmaceuticals from $10.00 to $8.00 and set a “buy” rating on the stock in a research report on Wednesday, November 15th.

NovaBay Pharmaceuticals (NBY) opened at $4.45 on Monday. NovaBay Pharmaceuticals has a 12-month low of $2.25 and a 12-month high of $5.00.

NovaBay Pharmaceuticals (NYSEAMERICAN:NBY) last announced its quarterly earnings data on Tuesday, November 14th. The biopharmaceutical company reported ($0.16) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.07) by ($0.09). The business had revenue of $4.09 million during the quarter, compared to the consensus estimate of $4.69 million. NovaBay Pharmaceuticals had a negative net margin of 42.16% and a negative return on equity of 184.30%.

TRADEMARK VIOLATION NOTICE: “NovaBay Pharmaceuticals, Inc. (NBY) Given Consensus Recommendation of “Hold” by Brokerages” was reported by American Banking News and is the sole property of of American Banking News. If you are viewing this news story on another website, it was stolen and reposted in violation of US & international copyright and trademark legislation. The legal version of this news story can be accessed at https://www.americanbankingnews.com/2017/11/27/novabay-pharmaceuticals-inc-nby-given-consensus-recommendation-of-hold-by-brokerages.html.

NovaBay Pharmaceuticals Company Profile

NovaBay Pharmaceuticals, Inc, formerly NovaCal Pharmaceuticals, Inc, is a biopharmaceutical company, which develops products for the eye care market. The Company focuses on commercializing prescription Avenova for managing hygiene of the eyelids and lashes in the United States. Avenova is an eye care product formulated with a form of hypochlorous acid called Neutrox.

Analyst Recommendations for NovaBay Pharmaceuticals (NYSEAMERICAN:NBY)

Receive News & Ratings for NovaBay Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NovaBay Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.